Ipsos Introduces Molecular Diagnostic Monitors

Ipsos Healthcare has launched a suite of Molecular Diagnostic Monitors, to provide a multi-stakeholder view of the global MDx (molecular diagnostics) market across multiple indications.

This new suite has been developed to complement the firm's existing Global Therapy Monitors, which track usage of treatments for more than 20 diseases in 31 countries.

Through the new monitor, Ipsos Healthcare will collect and incorporate data from a number of respondent types, including cancer-treating physicians, pathologists, and lab technicians/cytologists.

Perceptual data, such as awareness and attitudes towards currently available and future MDx tests, will also be collected alongside real patient-level and test-level data, to provide clients with an understanding of perceptions and testing behaviour.

The first product in the suite - the Oncology Molecular Diagnostics Monitor - is set to launch in Q2 2012, with first wave results available in Q3. Initial market coverage will include US and five EU markets (Germany, France, Italy, Spain, UK), with additional launches in Japan and APAC expected later this year.

Pieter De Richter (pictured), VP of Global Therapy Monitors, comments: 'We really are going for a complete picture of the entire MDx spectrum here; from initial diagnosis through to measuring disease progression. It is this comprehensive approach, combined with our unrivalled expertise and global footprint, which makes this new product truly unique.'

Web site: www.ipsoshealth.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• Ipsos UK
• All news
• MrWeb info